Edition:
United Kingdom

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.00USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$1.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
205,963
52-wk High
$8.37
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

vTv Therapeutics Qtrly GAAP Net Loss Per Share Was $0.31
Friday, 3 Aug 2018 

Aug 3 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 RESULTS AND UPDATE.VTV THERAPEUTICS INC - QTRLY GAAP NET LOSS PER SHARE WAS $0.31.VTV THERAPEUTICS INC - QTRLY REVENUE $2.5 MILLION VERSUS $13,000.  Full Article

vTv Therapeutics Announces Licensing Agreement With Newsoara Biopharma Co
Thursday, 31 May 2018 

May 31 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS ANNOUNCES LICENSING AGREEMENT WITH NEWSOARA BIOPHARMA CO. LTD. TO RIGHTS FOR VTV’S PDE4 INHIBITOR IN CHINA AND OTHER PACIFIC RIM TERRITORIES.VTV THERAPEUTICS INC - CO WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS - CO WILL BE ELIGIBLE TO RECEIVE FUTURE DEVELOPMENT & COMMERCIALIZATION MILESTONES AS WELL AS ROYALTIES ON SALES OF APPROVED PRODUCTS.VTV THERAPEUTICS INC - NEWSOARA WILL DEVELOP HPP737 IN COVERED TERRITORIES FOR RESPIRATORY AND OTHER INFLAMMATORY DISEASES.  Full Article

vTv Therapeutics Q1 GAAP Loss Per Share $0.30
Tuesday, 15 May 2018 

May 15 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS.Q1 GAAP LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON REUTERS I/B/E/S.  Full Article

Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL ALSO RECEIVE SHARES OF RENEO PHARMACEUTICALS' COMMON STOCK.  Full Article

vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM.VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES.VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS.  Full Article

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article

BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA

* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE